A Double-Blind Clinical Study in Patients with Herpes Zoster to Establish YN-72 (Brovavir) Dose
YN-72 (bromovinyl araU, or BV-araU) is a new antiviral agent synthesized by Yamasa Shoyu Company. It is an arabinosyluracil derivative having a bromovinyl group at the 5 position. Its chemical structure is shown in figure 1. YN-72 had potent in vitro antiviral action against varicella-zoster virus (VZV) and herpes simplex virus type 1 (HSV-1). Its proliferation-depressing action on normal cells is very low, and therefore the antiviral agent is highly selective (1–6). The mechanism of action is as follows: YN-72 is phosphorylated only by viral thymidine kinase to become a monophosphate and diphosphate. It is converted to a triphosphate by cellular kinase, which antagonizes the action of DNA polymerase, inhibiting viral proliferation (7–10).
KeywordsPlacebo Group Dose Group Herpes Zoster Effectiveness Rate Test Drug
Unable to display preview. Download preview PDF.
- 9.Ayisi, N. K., Wall, R. A., Wanklin, R. J., Machida, H., De Clercq, E. and Sacks, S. L. (1987) MoL PhannacoL 31, 422–429.Google Scholar